Clinical Trials on Tinea Cruris in Germany

Total 30 results

Bayer

Completed

Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo (Porsche)

Tinea Pedis

Germany
Almirall, S.A.

Completed

Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis

Tinea Pedis

Germany
photonamic GmbH & Co. KG

Completed

Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

Onychomycosis

Germany
Schülke & Mayr GmbH

Terminated

Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds

Ulcus Cruris

Germany
Charite University, Berlin, Germany

Completed

Effectiveness of Using an Oil Bath Additive

Xerosis Cutis

Germany
PD Dr. Jan Kottner

Completed

Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents

Xerosis Cutis

Germany
Galderma R&D

Completed

Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer (LOOP)

Foot Dermatoses

Germany
Polichem S.A.

Completed

Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population

Onychomycosis

Belgium, Germany, Italy, Latvia, Spain
Moberg Pharma AB

Completed

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Distal Subungual Onychomycosis

Germany, United Kingdom, Poland
Novartis

Completed

Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

Onychomycosis

France, Finland, Germany, Hungary, Iceland, Norway, Poland, Russian Federation, Spain, Turkey
Polichem S.A.

Completed

Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis

Onychomycosis

Belgium, Bulgaria, Czechia, Germany, Greece, Hungary, Iceland, Latvia, Lithuania, Poland, Russian Federation, Slovakia, Sweden
Galderma R&D

Completed

Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products

Xerosis Cutis

Germany
Blueberry Therapeutics
IQVIA Biotech

Completed

A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail

Fungal Infection | Distal Subungual Onychomycosis | Fungus, Nail

Poland, Germany, Czechia
Novartis Pharmaceuticals

Completed

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Onychomycosis

United States, France, Germany
Bayer

Completed

Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste

Onychomycosis

Germany, Poland, Czech Republic
University of Jena

Recruiting

European CML Blast Crisis Register (BlastCrisis)

Chronic Myeloid Leukemia in Myeloid Blast Crisis

Germany, Czechia, Russian Federation, Ukraine
PD Dr. Jan Kottner

Completed

Enhancing SKIN Health and Safety in Aged CARE (SKINCARE)

Pruritus | Intertrigo | Skin Care | Pressure Ulcer | Xerosis Cutis | Dry Skin | Incontinence-associated Dermatitis | Skin Tear

Germany
Augenklinik LMU

Completed

Effect of Compression Dressing After Upper Eyelid Blepharoplasty on Edema, Ecchymosis, Pain and Ocular Surface Irritation

Dermatochalasis of Eyelid

Germany
Goethe University

Completed

A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

Acute Lymphoblastic Leukemia | Leukemia, Myelocytic, Acute | Chronic Myelogenous Leukemia With Crisis of Blast Cells

Germany
Johann Wolfgang Goethe University Hospital

Unknown

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Philadelphia Positive Acute Lymphoblastic Leukemia | Lymphoid Blastic Phase of Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Philadelphia Chromosome Positive CML

United States, Germany, Italy, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Non-Hodgkin Lymphoma | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma

United States, Germany, Italy
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Leukemia, Myeloid, Chronic

United States, Germany
Pfizer

Active, not recruiting

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

Sickle Cell Disease | Vaso-occlusive Pain Episode in Sickle Cell Disease | Vaso-occlusive Crisis

United States, Oman, Colombia, Brazil, Lebanon, Nigeria, Germany, Italy, Kenya, Saudi Arabia, Tanzania, Turkey
Pfizer

Terminated

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Sickle Cell Disease | Vaso-occlusive Pain Episode in Sickle Cell Disease | Vaso-occlusive Crisis

United States, Oman, France, Brazil, Colombia, Lebanon, Nigeria, Germany, Italy, Kenya, Saudi Arabia, Turkey, United Kingdom, Zambia
Pfizer

Active, not recruiting

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Sickle Cell Disease | Vaso-occlusive Pain Episode in Sickle Cell Disease | Vaso-occlusive Crisis

United States, Oman, France, Brazil, Colombia, Egypt, Nigeria, Lebanon, Germany, Italy, Kenya, Saudi Arabia, Tanzania, Turkey, Zambia, Ghana, United Kingdom
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Chronic Myeloid Leukemia | Blast Crisis

Netherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
Incyte Biosciences International Sàrl

Recruiting

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Lymphoma | Acute Myeloid Leukemia | Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Solid Tumors | Chronic Phase Chronic Myeloid Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blast Phase Chronic Myeloid Leukemia

Spain, Italy, France, Germany, United Kingdom, Belgium, Sweden, Denmark, Netherlands
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Netherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic... and other conditions

United States, Germany, Denmark

Clinical Trials on Tinea Cruris in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations